Revolution Medicines, Inc.
NASDAQ:RVMDBiotechnology
+$3.60 today
- Market cap
- $34.57B
- Beta
- 1.41
- P/E (TTM)
- -23.3
- EPS (TTM)
- -$6.92
Volume 2.34M
Average 3.10M
RVMD Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Revolution Medicines, Inc.NASDAQ: RVMD
Short-term Investments · Q2 FY2026 · quarter ended Jun 2026
Short-term investments rises 80.0% from a year ago
Short-term investments stood at $3.12B at the end of Q2 FY2026, up 80.0% from a year earlier and up 112.8% from the prior quarter. Over 3 fiscal years it compounded at +50.3% a year.
Context
- Short-term investments amounted to 72.2% of total assets at the end of Q2 FY2026, up 0.8 pp from a year earlier.
- Short-term investments increased in 2 of the last 3 fiscal years.
What to watch
Whether short-term investments keeps rising in the next quarterly balance sheet after a +80.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 1.64B USD
- Year-over-year change
- -6.0%
- 4-year CAGR
- +36.8%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.64B | -6.0% |
| FY2024 | 2024-12-31 | 1.75B | +51.0% |
| FY2023 | 2023-12-31 | 1.16B | +139.2% |
| FY2022 | 2022-12-31 | 483.53M | +3.2% |
| FY2021 | 2021-12-31 | 468.56M | — |
Short-term Investments vs competitors
How RVMD compares with its peers on the latest reported figures
- RVMD's Jun 2026 short-term investments of $3.12B is the highest of the 11 companies compared; the peer median is $510.02M.
- Its year-over-year change of +80.0% is the 5th highest of 10, against a peer median of +63.4%.
- Short-term investments amounts to 72.2% of total assets for RVMD, versus a peer median of 59.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $3.12B | +80.0% | +50.3% | 72.2% | |
| Sep 2026 | $890.67M | +842.8% | -9.0% | 86.2% | |
| Jun 2026 | $789.75M | +45.5% | -17.8% | 81.6% | |
| Sep 2026 | $732.68M | +94.9% | — | 81.7% | |
| Sep 2026 | $524.74M | +140.5% | +10.1% | 52.5% | |
| Mar 2026 | $513.68M | -8.7% | +21.1% | 49.9% | |
| Mar 2026 | $506.36M | +104.6% | +5.9% | 68.8% | |
| Aug 2026 | $328.01M | -6.4% | +12.2% | 27.4% | |
| Mar 2026 | $225.54M | +46.1% | +19.1% | 51.6% | |
| Mar 2026 | $88.19M | +63.4% | +6.8% | 66.3% | |
| Mar 2026 | $16.13M | — | — | 7.1% | |
| Peer median (excluding RVMD) | $510.02M | +63.4% | +8.4% | 59.4% | |
Competitors are the stored peer set for RVMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 108.5M | 161.41M | 696.15M | 543.06M | 383.75M |
| Short-term Investments | 468.56M | 483.53M | 1.16B | 1.75B | 1.64B |
| Net Receivables | 5.93M | 4.67M | 1.25M | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 10.57M | 25.07M | 38.33M | 49.36M |
| Total Current Assets | 589.77M | 660.19M | 1.88B | 2.33B | 2.08B |
| Property, Plant & Equipment (Net) | 71.24M | 73.74M | 100.01M | 141.82M | 165.28M |
| Goodwill | 14.61M | 14.61M | 14.61M | 14.61M | 14.61M |
| Intangible Assets | 59.88M | 58.81M | 57.74M | 56.67M | 55.8M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 2.5M | 4.59M | 10.06M | 17.57M | 43.79M |
| Total Non-current Assets | 148.22M | 151.75M | 182.42M | 230.67M | 279.47M |
| Total Assets | 737.99M | 811.93M | 2.06B | 2.56B | 2.35B |
| Account Payables | 14.06M | 21.31M | 61.79M | 54.43M | 64.62M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 12.36M | 4.46M | 0 | 0 | 0 |
| Other Current Liabilities | 10.16M | 13.79M | 27.51M | 31.36M | 66.05M |
| Total Current Liabilities | 60.35M | 61.98M | 143.85M | 163.91M | 290.42M |
| Long-term Debt | 0 | 0 | 0 | 0 | 142.23M |
| Deferred Tax Liabilities | 7.44M | 7.03M | 3.12M | 2.35M | 2.35M |
| Deferred Revenue (Non-current) | 6.57M | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 634K | 301K | 7.97M | 3.86M | 288.2M |
| Total Non-current Liabilities | 75.07M | 64.76M | 91.66M | 129.18M | 432.79M |
| Total Liabilities | 135.42M | 126.74M | 235.51M | 293.1M | 723.21M |
| Common Stock | 8K | 9K | 16K | 18K | 19K |
| Retained Earnings | (452.64M) | (701.34M) | (1.14B) | (1.74B) | (2.87B) |
| Accumulated OCI | (376K) | (1.78M) | 544K | 1.32M | 3.24M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 602.57M | 685.19M | 1.83B | 2.27B | 1.63B |
| Total Debt | 66.63M | 64.21M | 87.94M | 135.84M | 158.7M |
| Net Debt | (41.86M) | (97.21M) | (608.2M) | (407.22M) | (225.04M) |
Revolution Medicines, Inc.
NASDAQ:RVMD
Intrinsic Alpha fair value
Locked
Current Price
$159.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.